GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Instituto Rosenbusch SA (BUE:ROSE) » Definitions » Cash-to-Debt

Instituto Rosenbusch (BUE:ROSE) Cash-to-Debt : 0.57 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Instituto Rosenbusch Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Instituto Rosenbusch's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.57.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Instituto Rosenbusch couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Instituto Rosenbusch's Cash-to-Debt or its related term are showing as below:

BUE:ROSE' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.09   Med: 0.2   Max: 0.57
Current: 0.57

During the past 13 years, Instituto Rosenbusch's highest Cash to Debt Ratio was 0.57. The lowest was 0.09. And the median was 0.20.

BUE:ROSE's Cash-to-Debt is ranked worse than
66.06% of 1037 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs BUE:ROSE: 0.57

Instituto Rosenbusch Cash-to-Debt Historical Data

The historical data trend for Instituto Rosenbusch's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Instituto Rosenbusch Cash-to-Debt Chart

Instituto Rosenbusch Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 0.31 0.30 0.31 0.38

Instituto Rosenbusch Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.27 0.28 0.38 0.57

Competitive Comparison of Instituto Rosenbusch's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Instituto Rosenbusch's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Instituto Rosenbusch's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Instituto Rosenbusch's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Instituto Rosenbusch's Cash-to-Debt falls into.


Instituto Rosenbusch Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Instituto Rosenbusch's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=390.782 / (435.763 + 598.084)
=0.38

Instituto Rosenbusch's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=573.659 / (441.035 + 562.345)
=0.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Instituto Rosenbusch  (BUE:ROSE) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Instituto Rosenbusch Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Instituto Rosenbusch's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Instituto Rosenbusch (BUE:ROSE) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Instituto Rosenbusch SA (BUE:ROSE) » Definitions » Cash-to-Debt
Comparable Companies
BSP:ARXD11 BSP:DMVF3 BSP:SNCI11 BSP:NUTR3 BSP:JOPA3 BSP:HUCG11 BSP:DTCY3 BSP:FATN11 BSP:DVFF11 BSP:BMIN3 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
N/A
Address
Hipolito Yrigoyen 1628, Buenos Aires, ARG, C1089AAF
Website
https://www.rosenbusch.com
Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.